Novo Nordisk EVP: Semaglutide can double obesity business in few years
Now that the FDA has approved Novo Nordisk's semaglutide as an injection treatment for obesity, the pharmaceutical company expects to double its sales of obesity drugs.
BY MAIKEN REIMER RØNNEBERG, TRANSLATED BY NIELSINE NIELSEN
Now that Danish pharmaceutical company Novo Nordisk has an approval from the US Food and Drug Administration (FDA) in place, Novo Nordisk is ready to launch the obesity drug Wegovy on the US market in late June.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Novo Nordisk's semaglutide as obesity treatment
For subscribers
Novo Holdings and Healthcap launch new biotech firm
For subscribers
